Evidence map›Paper›PMID 32895514›Full record

ArticleNature biomedical engineering2020

Gelling hypotonic polymer solution for extended topical drug delivery to the eye.

Yoo Chun Kim, Matthew D Shin, Sean F Hackett, Henry T Hsueh, Raquel Lima E Silva, Abhijit Date, Hyounkoo Han, Byung-Jin Kim, Amy Xiao, Youngwook Kim and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature biomedical engineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Fenofibrate microemulsion eyedrops for treating nitrogen mustard induced corneal injury.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  7. Article
  8. Drug Delivery Technologies for the Treatment of Age-Related Macular Degeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Evaluation ofFrontiers in bioengineering and biotechnology · 2025
    Article
  16. Article
  17. Hypotonic, gel-forming delivery system for vaginal drug administration.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Article
  18. Review
  19. Next generation therapeutics for retinal neurodegenerative diseases.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Yoo Chun KimCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Matthew D ShinCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-2516-5712
Sean F HackettDepartment of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Henry T HsuehCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Raquel Lima E SilvaDepartment of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-4325-5754
Abhijit DateCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Hyounkoo HanCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Byung-Jin KimDepartment of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-7456-5643
Amy XiaoCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Youngwook KimCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Laolu OgunnaikeCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Nicole M AndersThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Avelina HemingwayThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Ping HeThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Albert S JunDepartment of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Peter J McDonnellDepartment of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Charles EberhartDepartment of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ian PithaDepartment of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Donald J ZackCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Peter A CampochiaroDepartment of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-2531-8229
Justin HanesCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. hanes@jhmi.edu.ORCID http://orcid.org/0000-0001-9672-9821
Laura M EnsignCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. lensign@jhmi.edu.ORCID http://orcid.org/0000-0002-6949-7911

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
QAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7M
Wilmer Core Grant for Vision ResearchP30EY001765 · NEI · JOHNS HOPKINS UNIVERSITY · PI Jiang Qian · 1985 to 2026
$22.1M
Sustained-release of novel neuroprotective agents for treatment of glaucomaR01EY026578 · NEI · JOHNS HOPKINS UNIVERSITY · PI ENSIGN, LAURA · 2016 to 2020
$2.0M
Biomaterial Inhibitor of HIF-1 for Prolonged Anti-Angiogenesis in EyeR01EB016121 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI CAMPOCHIARO, PETER A, HANES, JUSTIN S. · 2015 to 2018
$1.7M
A novel hypotonic gelling eye drop for topical treatment of retinal degenerative diseasesR01EY031041 · NEI · JOHNS HOPKINS UNIVERSITY · PI CAMPOCHIARO, PETER A, ENSIGN, LAURA · 2020 to 2023
$1.6M
UPLC with Tandem MS for Sensitive Quantitative Analysis of Small MoleculesS10RR026824 · NCRR · JOHNS HOPKINS UNIVERSITY · PI RUDEK, MICHELLE A · 2010 to 2010
$429k
Acquisition of a triple quadrupole mass spectrometer for small molecule analysisS10OD020091 · OD · JOHNS HOPKINS UNIVERSITY · PI RUDEK, MICHELLE A · 2015 to 2015
$314k
NCATS NIH HHS UL1 TR001079NCATS NIH HHS UL1 TR003098NCI NIH HHS P30 CA006973NCRR NIH HHS S10 RR026824NEI NIH HHS P30 EY001765NEI NIH HHS R01 EY026578NEI NIH HHS R01 EY031041NIBIB NIH HHS R01 EB016121NIH HHS S10 OD020091
6 · The paper itself

Abstract

Eye-drop formulations should hold as high a concentration of soluble drug in contact with ocular epithelium for as long as possible. However, eye tears and frequent blinking limit drug retention on the ocular surface, and gelling drops typically form clumps that blur vision. Here, we describe a gelling hypotonic solution containing a low concentration of a thermosensitive triblock copolymer for extended ocular drug delivery. On topical application, the hypotonic formulation forms a highly uniform and clear thin layer that conforms to the ocular surface and resists clearance from blinking, increasing the intraocular absorption of hydrophilic and hydrophobic drugs and extending the drug-ocular-epithelium contact time with respect to conventional thermosensitive gelling formulations and commercial eye drops. We also show that the conformal gel layer allows for therapeutically relevant drug delivery to the posterior segment of the eyeball in pigs. Our findings highlight the importance of formulations that conform to the ocular surface before viscosity enhancement for increased and prolonged ocular surface contact and drug absorption.

Indexed as

Administration, TopicalAnimalsDrug Delivery SystemsEyeFemaleGelsHypotonic SolutionsMaleMice, Inbred C57BLNanoparticlesOphthalmic SolutionsPolymersRabbitsRats, Sprague-DawleySwineGelsHypotonic SolutionsOphthalmic SolutionsPolymers

Identifiers

PMID32895514
PMCPMC7655548

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.